Loading
A case report of one person with melanoma that no treatment had controlled, who went into a lasting remission after an infusion of their own helper T cells grown against the NY-ESO-1 protein.
The authors developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones specific for the melanoma-associated antigen NY-ESO-1 and infused them into a patient with refractory metastatic melanoma who had had no prior conditioning or cytokine treatment (New England Journal of Medicine 2008). The transferred cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1 (New England Journal of Medicine 2008).
Helper (CD4+) T cells, not only killer (CD8+) T cells, can drive a remission, and one targeted infusion can widen the immune response to other tumour antigens.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee.
Shares CTAG1B, Endogenous T-cell therapy, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/